Prophase Labs (PRPH)
OTHER OTC:PRPH
Want to see PRPH full AI Analyst Report?
Top Page
Prophase Labs
(OTC:PRPH)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.11
▼(-41.11% Downside)
Action:Reiterated
Date:06/06/26
The score is primarily held down by weak financial performance (large losses, sustained cash burn, and elevated leverage despite some 2025 improvement). Technicals add further pressure given negative momentum and the price sitting below key longer-term moving averages, while valuation offers little support due to negative earnings and no dividend yield.
Positive Factors
Proprietary BE‑Smart diagnostic asset
BE‑Smart is a clinically validated diagnostic that can be commercialized via a partner, which would unlock liquidity, lower ProPhase’s commercialization burden, and enable royalty or revenue‑sharing streams. A partner rollout provides durable distribution scale and reduces execution risk for ProPhase.
Negative Factors
Persistent negative cash flow
Multi‑year negative operating and free cash flow erodes liquidity and increases reliance on external financing or asset sales. This structural cash conversion weakness raises the probability of dilution or secured financing and constrains reinvestment in diagnostics or product commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary BE‑Smart diagnostic asset
BE‑Smart is a clinically validated diagnostic that can be commercialized via a partner, which would unlock liquidity, lower ProPhase’s commercialization burden, and enable royalty or revenue‑sharing streams. A partner rollout provides durable distribution scale and reduces execution risk for ProPhase.
Read all positive factors
Prophase Labs (PRPH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$949.33K
Dividend YieldN/A
Average Volume (3M)43.09K
Price to Earnings (P/E)―
Beta (1Y)2.03
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees96
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1.47
Shares Outstanding9,493,287
10 Day Avg. Volume71,279
30 Day Avg. Volume43,086
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.09
Price to Sales (P/S)0.88
P/FCF Ratio-0.43
Enterprise Value/Market Cap8.17
Enterprise Value/Revenue1.78
Enterprise Value/Gross Profit5.60
Enterprise Value/Ebitda-0.84
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.4
Revenue Forecast (FY)$41.69M
Prophase Labs Business Overview & Revenue Model
Company Description
ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Produc...
How the Company Makes Money
ProPhase Labs makes money primarily through (1) sales of consumer health/OTC products and (2) revenue from diagnostic testing and laboratory services (where operated). Consumer-product revenue is generated by selling branded OTC and wellness produ...
Prophase Labs Earnings Call Summary
Earnings Call Date:Nov 19, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted several promising developments, such as the Crown Medical collections, potential partnerships for the esophageal cancer test, and a turnaround in the Nebula Genomics business. However, these positives were counterbalanced by significant challenges, including financial constraints, a declining stock price, and the need for a reverse stock split to maintain Nasdaq compliance. The company is actively pursuing strategic initiatives to address these issues and improve shareholder value.Positive Updates
Crown Medical Collections Initiative
Crown Medical has been appointed special counsel to collect $150 million in uncollected COVID testing claims. They expect to collect at least $50 million net, which could significantly improve the company's financial situation.
Negative Updates
Stock Price and Market Cap Concerns
The company is facing a low market cap of around $12 million and a declining share price, which is affecting investor confidence and creating pressure to maintain Nasdaq compliance.
Read all updates
Q3-2025 Updates
Positive
Negative
Crown Medical Collections Initiative
Crown Medical has been appointed special counsel to collect $150 million in uncollected COVID testing claims. They expect to collect at least $50 million net, which could significantly improve the company's financial situation.
Read all positive updates
Company Guidance
During the ProPhase Labs, Inc.'s third-quarter 2025 earnings call, Chairman and CEO Ted Karkus provided several metrics and strategic insights. He emphasized the importance of shareholder voting on a critical proxy, which could impact strategic initiatives. The company is targeting collections of around $150 million in uncollected COVID testing claims, with expectations to net at least $50 million after discounts and fees. Karkus also discussed the potential of the BSmart esophageal cancer test, estimating a target market of $7-14 billion, and highlighted Nebula Genomics' restructuring towards profitability. ProPhase Labs' current market cap stands at approximately $12 million, with 46.1 million shares outstanding. Karkus addressed the possibility of a reverse stock split to maintain Nasdaq compliance, aiming to capitalize on the company's undervalued stock and significant asset potential.Prophase Labs Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
34
Negative
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.34M | 6.77M | 44.38M | 122.65M | 79.04M |
| Gross Profit | 1.38M | -150.00K | 16.24M | 70.65M | 32.81M |
| EBITDA | -11.39M | -32.34M | -14.83M | 28.73M | 11.39M |
| Net Income | -14.74M | -53.36M | -16.78M | 18.46M | 6.27M |
Balance Sheet | |||||
| Total Assets | 59.87M | 63.20M | 91.93M | 87.65M | 89.30M |
| Cash, Cash Equivalents and Short-Term Investments | 90.00K | 678.00K | 4.74M | 17.44M | 17.51M |
| Total Debt | 8.62M | 24.57M | 18.46M | 6.96M | 14.90M |
| Total Liabilities | 56.36M | 55.85M | 42.54M | 24.02M | 30.67M |
| Stockholders Equity | 3.51M | 7.35M | 49.38M | 63.63M | 58.63M |
Cash Flow | |||||
| Free Cash Flow | -8.94M | -18.44M | -14.50M | 24.63M | -17.85M |
| Operating Cash Flow | -8.94M | -17.54M | -11.35M | 28.55M | -13.62M |
| Investing Cash Flow | 920.00K | 2.42M | -1.37M | -2.08M | -19.67M |
| Financing Cash Flow | 6.84M | 14.19M | 5.76M | -26.02M | 35.13M |
Prophase Labs Technical Analysis
Negative
0.18
Price Trends
0.11
Negative
0.13
Negative
1.54
Negative
Market Momentum
>-0.01
Negative
44.57
Neutral
42.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRPH, the sentiment is Negative. The current price of 0.18 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.11, and below the 200-day MA of 1.54, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.57 is Neutral, neither overbought nor oversold. The STOCH value of 42.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRPH.
Prophase Labs Risk Analysis
Prophase Labs disclosed 63 risk factors in its most recent earnings report. Prophase Labs reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prophase Labs Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $21.76M | 121.56 | 0.27% | ― | 82.13% | ― | |
47 Neutral | $24.58M | -0.71 | -107.16% | ― | -18.24% | -2264.65% | |
47 Neutral | $7.56M | -2.83 | -40.66% | ― | 2.00% | 94.31% | |
42 Neutral | $949.33K | -0.06 | -404.42% | ― | ― | ― | |
42 Neutral | $1.84M | -14.53 | -93.87% | ― | -6.14% | -24.22% |
* Healthcare Sector Average
PRPH
Prophase Labs
0.10
-3.40
-97.14%
TXMD
TherapeuticsMD
1.88
0.67
55.37%
AYTU
Aytu BioScience
2.29
0.27
13.37%
YCBD
cbdMD
0.72
-0.18
-20.00%
IMCC
IM Cannabis Corp
0.30
-2.32
-88.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.